Comparative effectiveness and safety of ticagrelor and clopidogrel in patients with or without chronic liver disease: a nationwide cohort study
Although the effectiveness and safety of ticagrelor versus clopidogrel may differ in patients with chronic liver disease, there is a scarcity of evidence comparing ticagrelor and clopidogrel in patients with chronic liver disease. We aimed to evaluate the risk of major adverse cardiovascular events (MACE) and major bleeding associated with ticagrelor versus clopidogrel in patients undergoing percutaneous coronary intervention (PCI) due to acute coronary syndrome by chronic liver disease status. (Source: The American Journal of Medicine)
Source: The American Journal of Medicine - April 17, 2024 Category: General Medicine Authors: Bin Hong, Sungho Bea, Seng Chan You, Yoosoo Chang, Won Kim, Ju-Young Shin Tags: Clinical Research Study Source Type: research
Ticagrelor vs clopidogrel when coadministered with bivalirudin in patients with acute coronary syndrome undergoing percutaneous coronary intervention
CONCLUSION: As an initial treatment strategy, bivalirudin plus ticagrelor could reduce the 12-month risk of ischemic events compared with bivalirudin plus clopidogrel significantly without increasing the bleeding risk in ACS patients undergoing PCI.PMID:38623472 | PMC:PMC11017352 | DOI:10.1016/j.rpth.2024.102375 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - April 16, 2024 Category: Hematology Authors: Yang Li Yi Li Miaohan Qiu Yu Xue Kai Xu Yaling Han Source Type: research
Ticagrelor vs clopidogrel when coadministered with bivalirudin in patients with acute coronary syndrome undergoing percutaneous coronary intervention
CONCLUSION: As an initial treatment strategy, bivalirudin plus ticagrelor could reduce the 12-month risk of ischemic events compared with bivalirudin plus clopidogrel significantly without increasing the bleeding risk in ACS patients undergoing PCI.PMID:38623472 | PMC:PMC11017352 | DOI:10.1016/j.rpth.2024.102375 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - April 16, 2024 Category: Hematology Authors: Yang Li Yi Li Miaohan Qiu Yu Xue Kai Xu Yaling Han Source Type: research
Ticagrelor Versus Clopidogrel in Acute Large-Vessel Ischemic Stroke: A Randomized Controlled Single-Blinded Trial
ConclusionPatients with acute large-vessel ischemic stroke who received ticagrelor within the first 24 hours after ischemic stroke had better clinical outcomes based on recurrent stroke rates, NIHSS reduction, and favorable mRS rates compared with those who received clopidogrel. There were no differences between ticagrelor and clopidogrel regarding hemorrhagic and non-hemorrhagic complications.Trial RegistrationClinical trials.gov (NCT06120725). (Source: CNS Drugs)
Source: CNS Drugs - April 15, 2024 Category: Neurology Source Type: research
Feasibility and Safety of Bridging Antiplatelet Therapy with Cangrelor in Neuro-Oncology: A Preliminary Experience
J Neurol Surg A Cent Eur Neurosurg DOI: 10.1055/s-0044-1785649Antiplatelet therapy is mandatory for prevention of thrombotic events in patients with a recent history of acute coronary syndromes and/or percutaneous coronary interventions. However, if an urgent surgery is required during antiplatelet therapy, a compromise between the ischemic/thrombotic and hemorrhagic risk has to be reached. Different bridging schemes are reported in the literature, but there is no clear consensus on the optimal treatment strategy in terms of efficacy and safety. Although some indications about the perioperative management of antiplatelet t...
Source: Journal of Neurological Surgery Part A: Central European Neurosurgery - April 15, 2024 Category: Neurosurgery Authors: Bertolini, Giacomo Belli, Laura Mazza, Stefania Ugolotti, Pietro Tito Tadonio, Iacopo Ceccarelli, Patrizia Rossi, Sandra Ippolito, Salvatore Tags: Technical Note Source Type: research
Influence of sex on the timing of coronary angiography and the prescription of antiplatelet therapy in patients with nonST-segment elevation myocardial infarction
CONCLUSION: Women were more often prescribed less potent antithrombotic therapy than men. Frailty, but not sex, correlated independently with deferral of coronary angiography. However, we detected no differences in the frequency of coronary revascularization or in-hospital events according to sex.PMID:38597619 | DOI:10.55633/s3me/016.2024 (Source: Atherosclerosis)
Source: Atherosclerosis - April 10, 2024 Category: Cardiology Authors: Antonio Mart ínez-Guisado Pedro Cepas-Guill én Pablo D íez-Villanueva Mar ía Thiscal López Lluva Alfonso Jurado-Rom án Pablo Bazal-Chac ón Mart ín Negreira-Caamaño Iv án Olavarri-Miguel Ane Elorriaga Ricardo Rivera-L ópez David Escribano Pablo Source Type: research
Influence of sex on the timing of coronary angiography and the prescription of antiplatelet therapy in patients with nonST-segment elevation myocardial infarction
CONCLUSION: Women were more often prescribed less potent antithrombotic therapy than men. Frailty, but not sex, correlated independently with deferral of coronary angiography. However, we detected no differences in the frequency of coronary revascularization or in-hospital events according to sex.PMID:38597619 | DOI:10.55633/s3me/016.2024 (Source: Atherosclerosis)
Source: Atherosclerosis - April 10, 2024 Category: Cardiology Authors: Antonio Mart ínez-Guisado Pedro Cepas-Guill én Pablo D íez-Villanueva Mar ía Thiscal López Lluva Alfonso Jurado-Rom án Pablo Bazal-Chac ón Mart ín Negreira-Caamaño Iv án Olavarri-Miguel Ane Elorriaga Ricardo Rivera-L ópez David Escribano Pablo Source Type: research
De-escalation of antithrombotic treatment after acute coronary syndrome, a new paradigm
AbstractAfter an acute coronary syndrome (ACS) it is imperative to balance the bleeding vs. the ischemic risk given the similar prognostic impact of the two events. Since the post-discharge bleeding risk is substantially stable over time whereas the ischemic risk accumulates in the first weeks to months, a strategy of de-escalation of antithrombotic treatment, consisting in the reduction of either the duration (i.e., early interruption of one antiplatelet agent) or the intensity (i.e., switching from the more potent P2Y12-inhibitors prasugrel or ticagrelor to clopidogrel) of dual antiplatelet therapy (DAPT), has been propo...
Source: Internal and Emergency Medicine - April 10, 2024 Category: Emergency Medicine Source Type: research
Clopidogrel induced reduction in neutrophil count: An overlooked beneficial effect?
Eur J Intern Med. 2024 Apr 5:S0953-6205(24)00135-3. doi: 10.1016/j.ejim.2024.03.026. Online ahead of print.ABSTRACTComplement-stimulated neutrophils are able to adhere to the endothelium and damage endothelial cells both in vitro and in vivo. These blood cells participate in the early stages, growth and complications of atherosclerotic plaques. Recent findings, based on mendelian randomization analysis, support the concept that high neutrophil counts are a causal risk factor for ischemic heart disease and myocardial infarction . Clopidogrel decreases leukocyte count and inflammatory markers in patients with acute coronary ...
Source: European Journal of Internal Medicine - April 6, 2024 Category: Internal Medicine Authors: Stefano De Servi Antonio Landi Stefano Savonitto Source Type: research
Clopidogrel induced reduction in neutrophil count: An overlooked beneficial effect?
Eur J Intern Med. 2024 Apr 5:S0953-6205(24)00135-3. doi: 10.1016/j.ejim.2024.03.026. Online ahead of print.ABSTRACTComplement-stimulated neutrophils are able to adhere to the endothelium and damage endothelial cells both in vitro and in vivo. These blood cells participate in the early stages, growth and complications of atherosclerotic plaques. Recent findings, based on mendelian randomization analysis, support the concept that high neutrophil counts are a causal risk factor for ischemic heart disease and myocardial infarction . Clopidogrel decreases leukocyte count and inflammatory markers in patients with acute coronary ...
Source: European Journal of Internal Medicine - April 6, 2024 Category: Internal Medicine Authors: Stefano De Servi Antonio Landi Stefano Savonitto Source Type: research
Ticagrelor versus clopidogrel in dual antiplatelet therapy after minor stroke or transient ischemic attack: an updated network meta-analysis
ConclusionsDAPTs were superior to aspirin in preventing recurrence or ischemic stroke. Although no significant difference was observed between DAPTs, ticagrelor plus aspirin may be related to worse major bleeding results, including intracranial bleeding. Ticagrelor plus aspirin is a considerable option for patients after a minor stroke or TIA. (Source: Journal of Neurology)
Source: Journal of Neurology - April 5, 2024 Category: Neurology Source Type: research
Clinical impact of dyspnoea after ticagrelor treatment and the effect of switching to clopidogrel in patients with myocardial infarction
CONCLUSIONS: Dyspnoea is a common side effect among ticagrelor-based DAPT in AMI patients. Switching from ticagrelor to clopidogrel after 1 month in AMI patients may provide a reasonable option to alleviate subsequent dyspnoea in ticagrelor-relevant dyspnoeic patients, without increasing the risk of ischaemic events (NCT02018055).PMID:38574757 | DOI:10.1055/a-2299-4537 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - April 4, 2024 Category: Hematology Authors: Sang Hyun Kim Sanghoon Shin Eun Ho Choo Ik Jun Choi Sungmin Lim Donggyu Moon Chan Joon Kim Mahn-Won Park Min Chul Kim Byung-Hee Hwang Kwan Yong Lee Yun-Seok Choi Hee-Yeol Kim Ki-Dong Yoo Doo Soo Jeon Youngkeun Ahn Kiyuk Chang Source Type: research
Clinical impact of dyspnoea after ticagrelor treatment and the effect of switching to clopidogrel in patients with myocardial infarction
CONCLUSIONS: Dyspnoea is a common side effect among ticagrelor-based DAPT in AMI patients. Switching from ticagrelor to clopidogrel after 1 month in AMI patients may provide a reasonable option to alleviate subsequent dyspnoea in ticagrelor-relevant dyspnoeic patients, without increasing the risk of ischaemic events (NCT02018055).PMID:38574757 | DOI:10.1055/a-2299-4537 (Source: Thrombosis and Haemostasis)
Source: Thrombosis and Haemostasis - April 4, 2024 Category: Hematology Authors: Sang Hyun Kim Sanghoon Shin Eun Ho Choo Ik Jun Choi Sungmin Lim Donggyu Moon Chan Joon Kim Mahn-Won Park Min Chul Kim Byung-Hee Hwang Kwan Yong Lee Yun-Seok Choi Hee-Yeol Kim Ki-Dong Yoo Doo Soo Jeon Youngkeun Ahn Kiyuk Chang Source Type: research
Clinical study of tirofiban compared to low molecular weight heparin in the antithrombotic treatment of progressive pontine infarction
CONCLUSIONS: Tirofiban may be more effective and safer than LMWH in controlling the progression of acute pontine infarction, but further and large-sample studies are still needed to confirm this finding.PMID:38567581 | DOI:10.26355/eurrev_202403_35722 (Source: Pharmacological Reviews)
Source: Pharmacological Reviews - April 3, 2024 Category: Drugs & Pharmacology Authors: Q Zhou L-E Xu L-L Lin X-R Huang W-Z Chi J Lin P Lin Source Type: research
